Design, synthesis, in-vitro and in-silico studies of novel N- heterocycle based hydrazones as α-glucosidase inhibitors

dc.contributor.authorFarooqi, Rehmatullah
dc.contributor.authorUllah, Saeed
dc.contributor.authorKhan, Ajmal
dc.contributor.authorGurav, Shailesh S.
dc.contributor.authorMali, Suraj N.
dc.contributor.authorAftab, Hina
dc.contributor.authorAl-Sadoon, Mohammad Khalid
dc.date.accessioned2025-10-18T10:11:02Z
dc.date.created2025
dc.date.issued2025
dc.departmentBartın Üniversitesi
dc.description.abstractDiabetes mellitus has dominated the globe as a chronic health condition and has become a major global health concern. The inhibition of the key metabolic enzymes of carbohydrates digestion including alpha-amylase and alpha-glucosidase are the promising targets for the treatment of diabetes via delaying glucose absorption. Therefore, nitrogen containing saturated heterocycle (pyrrolidinyl, piperidinyl and N-methylpiperazinyl) based hydrazones derivatives 5-23 were synthesized through two step reactions and evaluated for their anti-diabetic potential. All compounds exhibited potent alpha-glucosidase inhibitory capability ranging (IC50 = 10.26-47.35 mu M), as compared to acarbose (IC50 = 871.40 +/- 1.24 mu M). Interestingly these derivatives also exhibited significant inhibitory capability against alpha-amylase with IC50 values in the range 25.81-76.05 mu M. Mechanistic study on the most potent compound indicated a competitive type of inhibition with a Ki value of 8.30 +/- 0.0076 mu M. Molecular docking was performed to predict binding interactions between receptor proteins and moiety. In QSAR analysis, through use of QSARINS different 1D and 2D descriptors were used to generate different models that enabled further identification of structural requirements that contributed to activity. pIC50 values were also predicted by QSAR model. Furthermore, in-silico ADMET and BOILED-egg model analysis showed that all analogues exhibited passive GI absorption, and all showed BBB penetration.
dc.description.sponsorshipKing Saud University, Riyadh, Saudi Arabia [RSP2025R410]
dc.description.sponsorshipThe authors would like to extend their sincere appreciation to the Researchers Supporting Project Number (RSP2025R410) , King Saud University, Riyadh, Saudi Arabia.
dc.identifier.doi10.1016/j.bioorg.2025.108155
dc.identifier.issn0045-2068
dc.identifier.issn1090-2120
dc.identifier.orcidFarooqi, Rehmatullah/0009-0009-7248-831X
dc.identifier.orcidGurav, Dr. Shailesh/0000-0002-7039-993X;
dc.identifier.pmid39826499
dc.identifier.scopus2-s2.0-85215387282
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.bioorg.2025.108155
dc.identifier.urihttps://hdl.handle.net/11772/22176
dc.identifier.volume156
dc.identifier.wosWOS:001401492300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofBioorganic Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzWoS_20251016
dc.subjectHydrazones
dc.subjectAlpha-Glucosidase
dc.subjectAlpha-Amylase
dc.subjectDiabetes Mellitus
dc.subjectMolecular Docking
dc.subjectQsar
dc.titleDesign, synthesis, in-vitro and in-silico studies of novel N- heterocycle based hydrazones as α-glucosidase inhibitors
dc.typeArticle
dspace.entity.typePublication

Dosyalar